Dicerna to Present at Jefferies 2017 Global Healthcare Conference
June 01 2017 - 7:30AM
Business Wire
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading
developer of investigational ribonucleic acid interference (RNAi)
therapeutics, today announced that Douglas M. Fambrough, Ph.D.,
president and chief executive officer, will present at the
Jefferies 2017 Global Healthcare Conference on Friday, June 9,
2017, at 11:30 a.m. ET. The conference will be held at the Grand
Hyatt New York in New York City.
A live webcast of the presentation can be accessed on the
Investors & Media section on the Dicerna website at
www.dicerna.com. An archived replay of the webcast will be
available on the Company’s website after the conference.
About Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company
focused on the discovery and development of innovative ribonucleic
acid interference (RNAi)-based therapeutics for diseases involving
the liver, including rare diseases, chronic liver diseases,
cardiovascular diseases, and viral infectious diseases. The Company
is leveraging its proprietary GalXC™ RNAi technology platform to
build a broad pipeline in these core therapeutic areas, focusing on
target genes where connections between target gene and diseases are
well understood and documented. The Company intends to discover,
develop and commercialize novel therapeutics either on its own or
in collaboration with pharmaceutical partners. For more
information, please visit www.dicerna.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170601005235/en/
Investors:Rx Communications GroupPaula Schwartz,
917-322-2216pschwartz@rxir.comorMedia:SmithSolveAlex Van
Rees, 973-442-1555 ext. 111alex.vanrees@smithsolve.com
Dicerna Pharmaceuticals (NASDAQ:DRNA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dicerna Pharmaceuticals (NASDAQ:DRNA)
Historical Stock Chart
From Apr 2023 to Apr 2024